Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25531588 | 1.00 | GSK3B (0.34) | GSK3BDYRK1ATRPV1FAAHDPP4 | |
| Hydrochloric Acid SCHEMBL22233296 | 0.99 | GSK3B (0.33) | GSK3BDYRK1ATRPV1FAAHDPP4 | |
| Hydrochloric Acid SCHEMBL22233291 | 0.99 | GSK3B (0.33) | GSK3BDYRK1ATRPV1FAAHDPP4 | |
| Hydrochloric Acid SCHEMBL30400822 | 0.99 | GSK3B (0.33) | GSK3BDYRK1ATRPV1FAAHDPP4 | |
| SCHEMBL22233796 | 0.93 | GSK3B (0.35) | GSK3BDYRK1ATRPV1FAAHDPP4 | |
| Hydrochloric Acid SCHEMBL22233632 | 0.92 | GSK3B (0.34) | GSK3BDYRK1ATRPV1FAAHDPP4 | |
| Hydrochloric Acid SCHEMBL30398715 | 0.92 | GSK3B (0.34) | GSK3BDYRK1ATRPV1FAAHDPP4 | |
| SCHEMBL25531340 | 0.92 | EPHX2 (0.37) | GSK3BDYRK1ATRPV1FAAHEPHX2 | |
| SCHEMBL22255228 | 0.92 | EPHX2 (0.37) | GSK3BDYRK1ATRPV1FAAHEPHX2 | |
| Hydrochloric Acid SCHEMBL22233845 | 0.91 | EPHX2 (0.37) | GSK3BDYRK1ATRPV1FAAHEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159491-A1 | Antimicrobial Compounds and Methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-25 | — | — | US | disclosed |
| US-20230159491-A1 | Antimicrobial Compounds and Methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-25 | — | — | US | disclosed |
| WO-2020150385-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | CURZA GLOBAL, LLC (US) | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159491-A1 | Antimicrobial Compounds and Methods | MPO, NISCH, RPN2 | GSK3B 1762/4885DYRK1A 3645/4885TRPV1 848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.